Kreutzberger A
Arzneimittelforschung. 1978;28(10):1684-7.
In view of the tumor inhibitory activity of various pyrimidine derivatives, investigations aimed at the structure modification of barbituric acids were performed. In accordance with the aminomethinylation principle, barbituric acids (2) are converted into 5-formimidoylbarbituric acids (4) by s-triazine (1). Aside from the free barbituric acid (2a), both 1-substituted (2b, d, and f) and 1,3-di-substituted (2c, e, and g) barbituric acids are amenable to this reaction. After introduction of the formimidoyl group into 5-position of the barbituric acid ring system, marked tumor inhibitory effects against lymphoma, lymphocytical leukemia, and luekemia L-1210, are ascertainable.
鉴于各种嘧啶衍生物的肿瘤抑制活性,开展了旨在对巴比妥酸进行结构修饰的研究。根据氨基甲酰化原理,通过s-三嗪(1)将巴比妥酸(2)转化为5-甲酰亚胺基巴比妥酸(4)。除了游离巴比妥酸(2a)外,1-取代(2b、d和f)和1,3-二取代(2c、e和g)的巴比妥酸都适用于此反应。在将甲酰亚胺基引入巴比妥酸环系的5-位后,可确定其对淋巴瘤、淋巴细胞白血病和白血病L-1210具有显著的肿瘤抑制作用。